Markets

Early-stage immuno-oncology biotech TCR2 Therapeutics sets terms for $75 million IPO

A person taking notes from their tablet
Credit: Shutterstock photo

TCR2 Therapeutics, an early-stage biotech developing T cell immunotherapies for various cancers, announced terms for its IPO on Friday.

The Cambridge, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. Insiders intend to purchase $30 million worth of shares in the offering. At the midpoint of the proposed range, TCR2 Therapeutics would command a fully diluted market value of $374 million.

TCR2 Therapeutics was founded in 2015 and plans to list on the Nasdaq under the symbol TCRR. Jefferies, SVB Leerink and BMO Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of February 11, 2019.

The article Early-stage immuno-oncology biotech TCR2 Therapeutics sets terms for $75 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs